Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether adding inavolisib with a CDK4/6 inhibitor and letrozole improves efficacy and safety versus placebo with a CDK4/6 inhibitor and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor
• Inavolisib (Inavolisib)
• Letrozole (letrozole)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING